<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3014">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01702701</url>
  </required_header>
  <id_info>
    <org_study_id>MCWEoEMVF</org_study_id>
    <nct_id>NCT01702701</nct_id>
  </id_info>
  <brief_title>Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone</brief_title>
  <official_title>Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare response to treatment of Eosinophilic Esophagitis with montelukast
      vs standard therapy fluticasone. Investigators hypothesize that montelukast is equally
      effective in treating symptoms and histology of EoE when compared to fluticasone. The study
      will be conducted at multiple sites with Medical College of Wisconsin as the coordinating
      site. After identification and recruitment all patients will be randomized (provider
      blinded) to one of two medications: montelukast 10mg po qday vs fluticasone 440mcg po bid.
      Patients will also complete a pretreatment, 6 week therapy and 12 week therapy questionaire.
      They will then undergo a repeat endoscopy to evaluate endoscopic and histologic response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eosinophilic esophagitis is an allergic condition of the esophagus with an incidence that is
      on the rise, and has limited treatment options. Current gold standard of treatment is with
      topical steroids (swallowed fluticasone). There is preliminary data that oral montelukast
      may prove to be effective in inducing and maintaining symptomatic along with histologic
      remission of this disease. Investigators will be comparing the effectiveness of singulair to
      swallowed fluticasone in inducing and maintaining histologic and symptomatic remission of
      eosinophilic esophagitis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in Dysphagia symptom score</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in esophageal histology counts of eosinophils/hpf</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <condition>Dysphagia</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 10 mg po montelukast daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 440mcg fluticasone po bid for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>montelukast 10mg po pill q day for 12 weeks</description>
    <arm_group_label>Montelukast</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>fluticasone 440mcg po q bid x 12 weeks</description>
    <arm_group_label>Fluticasone</arm_group_label>
    <other_name>Flovent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a confirmed diagnosis of EoE on biopsy

          -  with &gt;15 eos per HPF

          -  ages &gt;18

          -  Both male and Female.

          -  Not pregnant

        Exclusion Criteria:

          -  pregnancy

          -  patients receiving ongoing medical therapy for EoE

          -  patients who underwent dilation in the last 12 weeks with improvement in symptoms

          -  LA grade B or worse erosive esophagitis.

          -  age &lt; 18

          -  nursing mothers

          -  use of prohibited concomitant medications : budesonide-oral compounded liquid,
             fluticasone or montelukast.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Hogan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikhil Shastri, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Associates</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>November 21, 2012</lastchanged_date>
  <firstreceived_date>October 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deglutition Disorders</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
